Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Overview of attention for article published in Cardiovascular Diabetology, October 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 5 X users

patent: 1 patent

Citations

dimensions_citation: 112 Dimensions

Readers on

mendeley: 63 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 9,695 followers.

https://t.co/LM7pVLUXSC Un nuevo medicamento en fase experimental que reduce los triglicéridos sin efectos secundarios significativos.

28 Mar 2019

Reply Repost Favourite

RT @syuichiao89: ペマフィブラート https://t.co/fHvTphxxka https://t.co/NTbfGfLHJW https://t.co/BvlhwoAbYh https://t.co/wGIGdHP8uK https://t.co/lGwY…

12 Jun 2018

Reply Repost Favourite

ペマフィブラート https://t.co/fHvTphxxka https://t.co/NTbfGfLHJW https://t.co/BvlhwoAbYh https://t.co/wGIGdHP8uK https://t.co/lGwYVJbJvO https://t.co/KULg0mj0A8 https://t.co/VhJsLXdFE9 https://t.co/uktBkIjTnX https://t.co/wERmY00ipJ https://t.co/uktBkIjTnX

12 Jun 2018

Reply Repost Favourite

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia https://t.co/4OWcD2IN4W

12 Jun 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.